Implanet Strengthens JAZZ Intellectual Property Portfolio

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

IMPLANET (Paris:IMPL) (OTCQX:IMPZY) (Euronext Growth: ALIMP, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces that the US Patent and Trademark Office (USPTO) has granted two new patents for the JAZZ™ platform.

Advertisement

These two new patents further strengthen the portfolio of 22 patents covering all the aspects of the JAZZ™ platform. It is the result of an extremely proactive and rigorous policy that is one of the strategic keys to commercial development and value creation.

Régis Le Couedic, Implanet’s Product Development & Manufacturing Director, says: “These two new U.S. patents expand our protection on this highly competitive market. Intellectual Property is essential to Implanet’s formula, we meticulously manage our portfolio. Clinical results support the fact that we possess the band market’s most advanced implants and instrumentation. We will continue to expand the scope of protection covering our JAZZ™ platform and future innovations.”

Ludovic Lastennet, CEO of Implanet, adds: “Obtaining these patents is an integral part of our value-creation strategy, we aim to put solid barriers in place in an addressable spine market estimated at $2.1 billion. The systematic growth of our IP protection enables us to reinforce our current commercial partnerships and look towards future strategic alliances.”

Next financial press release: revenue for the 3^rd quarter of 2017, on October 10, 2017, before market opens.

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ™ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ™ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2016 sales of €7.8 million. For further information, please visit www.implanet.com. Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013. IMPLANET is listed on Euronext™ Growth market in Paris.

Disclaimer

This press release contains forward-looking statements concerning Implanet and its activities. Such forward looking statements are based on assumptions that Implanet considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Implanet registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on April 26, 2016 under number R.16-035 and available on the Company’s website (www.implanet-invest.com), and to the development of economic situation, financial markets, and the markets in which Implanet operates. The forward-looking statements contained in this release are also subject to risks unknown to Implanet or that Implanet does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Implanet that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for Implanet shares in any country.